New Zealand leads the age standardised prostate cancer incidence rates in the world. Overall, only 26% of men over 40 years of age get prostate screening with prostate-specific antigen (PSA) in New Zealand. Our studies from Auckland indicate that 55% of diagnoses occur when the prostate cancer reaches high-risk status. The cumulative costs of managing high-risk prostate cancer is double the cost for low-risk disease. Our mainly European Auckland patient cohort showed that age-based PSA vary with genetics and lifestyle indicating a requirement for stratified PSA thresholds for better utility. However, we wish to evaluate whether this variability exists throughout New Zealand. Towards this requirement, we have to build relationships and trust with the end-users, including the island-wide urology/oncology clinical staff, general practitioners, Māori-Pacific leadership and social groups towards recruitment of an equitable patient cohort for such an analysis. Therefore, this application is towards relationship and trust building aspect for the future study.